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 The adaptive immune system utilizes tightly regulated signaling networks to fight 
off pathogens while remaining controlled enough to avoid harmful conditions like 
autoimmunity and cancer.  While many of the steps in antigen receptor signaling are well 
characterized, some of the mechanisms and proteins that are active in these pathways 
remain unknown.  This thesis identifies a potential modulator of NF-κB signaling in the 
antigen receptor pathways.  A protein-protein interaction screen was conducted to 
identify proteins which interact with the scaffolding molecule CARD11.  Secondary 
screening of the initial hits identified C9orf9 as a potential modulator of signaling in the 
pathways of interest.   Knockdown studies identified a specific role for C9orf9 in antigen 
receptor-to-NF-κB signaling, but not in antigen receptor-to-NFAT signaling or TNF-to-
NF-κB signaling.  Significantly, these knockdown studies also confirmed the presence of 
two isoforms of C9orf9 in Jurkat T cells.  While it was not possible to separate the 
functions of the two isoforms in Jurkat T cells, knockdown of both isoforms led to 
changes in phosphorylation and activation of pathway proteins, which could explain the 
role of C9orf9 in modulating NF-κB activity.  Studies in 293T cells showed that C9orf9 
interacts with several members of the CARD11 signaling complex, including Bcl10.  
Interestingly, C9orf9 has the ability to enhance the signaling capabilities of hyperactive 
CARD11 variants as well as Bcl10.  This was true regardless of the mechanism of action 
of the hyperactive CARD11 variants.  A knockout mouse was generated using 
CRISPR/Cas9 technology in the hope that the removal of C9orf9 would lead to a defect 
in B and/or T cell development or activation.  While this was not observed, C9orf9 
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knockout mice were born slightly out of Mendelian ratios in a pattern that mimics the one 
seen in Bcl10 knockout mice.  This observation, as well as the ability of C9orf9 to 
associate with Bcl10, suggests that the ability of C9orf9 to modulate NF-κB signaling 
may hinge on the interplay between the two isoforms of C9orf9 and Bcl10.  This work 
introduces C9orf9 into the pantheon of antigen receptor signaling proteins and suggests 
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Antigen receptor signaling 
The adaptive immune system is a highly regulated network of cells that respond 
to external stimuli to produce a specific, targeted immune reaction.  It defends against a 
wide variety of pathogens to prevent host illness.  Antigen presenting cells (APCs) such 
as dendritic cells (DCs) process antigen from the host environment and display fragments 
of antigen on their surface via their major histocompatibility complex (MHC) molecules.  
T cells and B cells receive this information via their antigen receptors, known as B cell 
receptors (BCRs) and T cell receptors (TCRs).  This antigen receptor signaling gets 
transduced through a complex system of pathways and leads to various growth and 
development signals.  When these pathways malfunction, the immune system can react in 
a number of harmful ways.  Innocuous antigens may be attacked, leading to allergy and 
autoimmunity.  A harmful antigen may be ignored, which allows cancer cells to slip 
through the immune screening mechanisms.  Or, immune cells may fail to regulate their 
own growth, leading to leukemias and lymphomas. 
 Antigen receptor activation induces the activation of many genes required for the 
adaptive immune response.  These genes can include pro-inflammatory cytokines such as 
IL-2, IL-6, TNFα, and IFNγ and their respective receptors [1].  Target genes of antigen 
receptor signaling may also include pro-survival genes such as Bcl2 and Bim, various cell 
adhesion molecules, and molecules involved in antigen presentation [1].  There are 
several key transcription factors activated during antigen receptor signaling, including 
NF-κB (Nuclear Factor κB), NFAT (Nuclear Factor of Activated T cells), and AP-1 
(Activator Protein 1).  NF-κB is a family of critical transcription factors for the adaptive 
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immune response.  Its targets are responsible for many of the processes just described, 
including cell survival and proliferation as well as effector functions like cell-specific 
killing.  There are 5 members of the NF-κB family, including p50 (NF-κB1), p52 (NF-
κB2), p65 (RelA), RelB, and c-Rel [2].   
 In the absence of signaling, the NF-κB dimers are bound to the protein IκBα 
(Inhibitor of κB alpha) and are sequestered in the cell cytoplasm [2].  Under optimal 
conditions, NF-κB is only released to the nucleus when IκBα is phosphorylated, 
ubiquitinated, and degraded as a result of antigen receptor signaling.  However, because 
of the complex nature of the antigen receptor signaling network, there are many 
opportunities for proteins to malfunction and cause constitutive activation of the pathway.  
This removes the requirement for specific, controlled antigen receptor signals to be 
transduced through the pathway and allows for continuous engagement of growth and 
activation pathways as a result of unrestricted NF-κB activity. 
CARD11 is a multidomain scaffolding protein found downstream of the antigen 
receptors in both B and T cells and upstream of NF-κB [3-5]. In the absence of signaling, 
CARD11 resides in a closed, inactive conformation. Upon antigen receptor engagement, 
signals are transduced through a network of proteins that lead to the phosphorylation of 
CARD11 by PKCθ in T cells and PKCβ in B cells [6,7].  After phosphorylation, 
CARD11 transitions from its closed, inactive conformation to an open, active 
conformation [8].   This transition is controlled by an Inhibitory Domain (ID), which 
interacts with the CARD (Caspase Activation Recruitment Domain), LATCH, and Coiled 
Coil domains and blocks recruitment of signaling cofactors to CARD11 [9,10].  In its 
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open state, CARD11 recruits a complex of signaling molecules to its N-terminal domains 
(Figure 1).  These molecules include Bcl10, whose ubiquitination is required for 
functional signaling [11].  Other molecules recruited to the complex include the 
paracaspase MALT1 (Mucosal Associated Lymphoid Tissue 1), the E3 ubiquitin ligase 
TRAF6, the TNF-responsive signaling protein TAK1, Caspase8, and the regulatory 
subunit of the IKK complex IKKγ (also called NEMO) [9].  Several residues of CARD11 
including S564, S567, S577, S649, and S657 can be phosphorylated by PKC, IKKβ, and 
at least one other kinase [6, 7, 12-14].  Phosphorylation of these residues is thought to 
disrupt the intramolecular binding of the ID with the CARD and coiled-coil domains, and 
thereby allows the protein to transition from its closed to open state.   
 While many of the components of the Antigen Receptor-to-NFκB pathway are 
known, the exact mechanism by which CARD11 signals to the IKK complex is unclear.   
In both T cells and B cells, the steps upstream of CARD11 are well established.  In T 
cells, signals are received via the TCR and CD3 complex.  The CD3 accessory chains are 
transmembrane proteins that contain cytoplasmic ITAMs (immunoreceptor tryrosine-
based activation motifs) [15, 16]. After Antigen presenting cells (APCs) present antigen 
to the TCR, the CD3 ITAMs are phosphorylated by the kinase Lck [16, 17].  This 
phosphorylation allows for the recruitment of ZAP-70 (ζ-associated protein of 70-kDa), a 
Syk family kinase which phosphorylates LAT (Linker of Activated T cells), and SLP-76 
(SH2-domain-containing leukocyte protein of 76-kDa) among other targets. LAT and 
SLP-76 recruit and activate many other signaling proteins that lead to activation of 
transcription factors and pro-survival programs [15].  PLCγ (Phosholipase C γ) is among 
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the proteins recruited by LAT and SLP-76.  PLCγ catalyzes the separation of PIP2 into 
IP3 and DAG (diacylglycerol) [15].  While IP3 activates calcium-based signaling 
pathways that activate the transcription factor NFAT, DAG phosphorylates PKC and 
leads to the activation of CARD11 signaling to NF-κB [18].  BCR signaling is very 
similar to TCR signaling.  
 The BCR is a membrane-bound antibody whose parent DNA has undergone 
V(D)J recombination to become antigen specific.  At the cell surface the BCR is 
associated with CD79 molecules that serve a similar function to CD3 in T cells.  After the 
BCR is activated by antigen crosslinking, the cytoplasmic ITAMs of CD79 are 
phosphorylated [19].  The activated ITAMs recruit the kinase Syk, the B cell correlate to 
ZAP-70 [20], which leads to the recruitment of PLCγ.  As in T cells, PLCγ catalyzes the 
separation of  PIP2 into IP3 and DAG which then go on to activate their respective 
signaling pathways [21].   
While the steps between engagement of the antigen receptor and the 
phosphorylation of CARD11 by PKC are well characterized in both B and T cells, the 
steps downstream of CARD11 activation are somewhat less well known.  Although six 
signaling cofactors of CARD11 have been identified, the exact mechanism by which this 
signaling complex activates the IKK complex is as yet unknown.  I therefore hypothesize 
the existence of one or more previously unknown components of this pathway that may 
regulate CARD11 function or assist in the transduction of signals from the CARD11 
complex to the IKK complex.  Some of these unknown signaling cofactors may also be 
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relevant in DLBCL and BENTA disease and have the potential to serve as therapeutic 
targets in these patients.   
Diffuse Large B cell Lymphoma (DLBCL) is the most common type of Non-
Hodgkin’s Lymphoma, comprising 30-40% of cases [22].  The three subtypes of DLBCL 
are the Activated B Cell –Like (ABC), Germinal Center B (GCB), and primary 
mediastinal B cell lymphoma.  While about 50% of DLBCL cases are curable, the ABC 
subtype is the least responsive to treatment [23].  The ABC subtype is known for its 
reliance on constitutive, canonical NF-κB signaling [24].  This constitutive signaling can 
be caused by mutations in a number of proteins in the NF-κB pathways, including 
CARD11.  In fact, one group found CARD11 coiled coil domain mutations in about 10% 
of their patient samples [25].  An immortalized cell line made from one DLBCL patient 
and carrying a hyperactive CARD11 mutant fails to survive in the absence of CARD11 
and dies rapidly after CARD11 loss [25].  Transfection with a number of different 
CARD11 gain of function mutants, including its original endogenous mutant, rescues this 
survival phenotype and indicates that CARD11 mutants are drivers of oncogenesis in 
these cancers [25].   
BENTA (B Cell Expansion with NF-κB and T cell Anergy) disease is a recently 
described condition characterized by B cell lymphocytosis and T cell anergy [26-28].  
These patients have elevated numbers of mature naïve B cells but decreased memory B 
cells.  Their CD3+ T cell numbers are lower than expected, and fail to proliferate under 
stimulation and have lower IL-2 secretion than healthy controls.  The patients described 
in these papers have heterozygous germline gain of function mutations of CARD11 
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including C49Y, G123D, and G116S.  Interestingly, the G123D mutation has also been 
found in DLBCL patients [29], suggesting that these mutations alone are a “first hit” and 
are not enough to cause lymphomagenesis without another mutagenic hit to genes in the 
pathway.  Understanding the role of CARD11 modulators could help identify potential 


















Protein-Protein Interaction Screen 
In order to identify potential CARD11 interactors, I performed a protein-protein 
interaction screen using a recombinant form of CARD11.  I created two different versions 
of CARD11, both with N-terminal V5 and myc tags and C-terminal 6xHis tags.  The first 
version, called ΔID, contains wild type versions of the N-terminal CARD, LATCH, and 
Coiled Coil domains of CARD11.  It serves as a truncated version of the hyperactive ΔID 
version of CARD11 which lacks the autoinhibitory domain and is known to have higher 
binding affinity for CARD11 cofactors such as Bcl10.  The second recombinant version 
of CARD11 includes both the ID and the hyperactive L251P mutation.  Although this 
construct contains the autoinhibitory domain, the L251P mutation is hyperactive and the 
construct also has higher affinity for Bcl10 than wild type CARD11 does.  I hypothesized 
that these two constructs would specifically bind to proteins that are recruited to the 
CARD11 complex under hyperactive, constitutive signaling conditions and help 
understand the signaling pathway in oncogenic contexts.  I excluded the CARD11 C-
terminal PDZ-SH3-GUK domains because very little is known about the role of these 
domains in CARD11 signaling.  I wanted to specifically identify proteins that interact 
with the domains of CARD11 which are known to play a role in signaling and which are 
known to have oncogenic mutations.   
I expressed these two constructs in bacteria and used the 6X His tag to purify the 
protein from the lysate using nickel beads.  Because CARD11 tends to precipitate out of 
solution, I expressed the protein in very large quantities in order to isolate enough protein 
for our interaction studies.  I then partnered with the Johns Hopkins High-Throughput 
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(HiT) Center to perform a chip-based protein-protein interaction study.  This technique 
resembles a Far Western, but is performed on a glass slide rather than on a membrane.  
Coated glass slides were printed with 17,000 GST-tagged proteins in duplicate, incubated 
with isolated rCARD11 protein, and detected with an anti—V5 antibody.  A CY5-
conjugated secondary antibody was used to amplify the V5-specific signal, and the chip 
was read on an Axon GenePix Scanner.  A third chip was also incubated with the V5 and 
secondary antibodies to rule out any non-specific detection.  GenePix Pro 6.0 software 
was used to analyze the fluorescent intensity of each signal and match it with the layout 
of the proteins printed on the chip.  A protein had to have both of its printed samples 
fluoresce to be considered a positive hit. 
The top 0.5% of fluorescent intensities for each chip were calculated and 
identified.  Proteins with known functions unrelated to antigen receptor signaling such as 
tRNA synthetases were discarded from the analysis.  Also eliminated were proteins 
which are not known to express in the immune system, but proteins which express at 
globally low levels throughout the body were retained.  This in silico analysis left 63 
proteins which were subjected to secondary screening.  Secondary screening involved 
examining two different indicators of a protein’s relevance to antigen receptor and 
CARD11 signaling.  The first requirement was that it interact with CARD11, so co-
immunoprecipitations were performed in HEK293T cells using cDNAs obtained from the 
HiT Center and our standard murine CARD11 constructs.  cDNAs were obtained from 
our HiT Center in Entry Vectors, and Gateway cloning was used to clone each cDNA 
into a destination vector containing an N-terminal V5-tag.  For immunoprecipitation 
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assays, the V5-tagged test clone was co-transfected into 293s with myc-tagged wild type, 
ΔID, or L251P CARD11 using the calcium phosphate method.  Cells were harvested and 
lysed in IP lysis buffer (50mM HEPES pH7.9, 150mM NaCl, 1mM EDTA, 10% 
glycerol, 1% IGEPAL).  The V5 tagged proteins were pulled down with anti-V5 
antibodies and Protein G Sepharose beads.  Lysates were run on SDS-PAGE and 
transferred to PVDF.  Membranes were blotted with anti-V5 antibodies to detect the test 
proteins and anti-myc antibodies to determine the interaction with the CARD11 
constructs.  Test proteins which specifically interacted with hyperactive ΔID and L251P 
CARD11 but not wild type CARD11 were considered to be relevant for understanding 
hyperactive CARD11 signaling. 
Finally, test proteins were evaluated on their ability to affect CARD11 signaling 
to NF-κB via a luciferase reporter assay.  The same V5-tagged proteins were transfected 
into HEK293T cells (293s) along with an NF-κB responsive luciferase reporter and a 
constitutively active β-galactosidase construct to control for transfection efficiency and 
sample recovery.  Each V5-tagged test construct was tested with wild type CARD11, the 
oncogenic mutant L251P, and a hyperactive variant of CARD11 in which the 
autoinhibitory domain has been deleted (ΔID).  Because I was interested in understanding 
the mechanisms of CARD11-initiated oncogenesis, I was particularly interested in test 
constructs which enhanced the hyperactive variants of CARD11. The most promising 
candidate from the luciferase reporter assays was a small, 168 amino acid construct 
which significantly enhanced ΔID and L251P CARD11 activity.  This construct also 
enhances WT CARD11 activity, although to a lesser extent (Figure 2).  This construct 
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was identified as C9orf9, an uncharacterized gene on Chromosome 9.  Very little is 
known about C9orf9.  Sequence analysis reveals no known domains, nor any homology 
to other proteins. Despite this lack of domain homology, C9orf9 is relatively well 
conserved in higher order mammals.   
C9orf9 is an enhancer of CARD11 signaling 
Five shRNA constructs against C9orf9 made from sequences identified by Sigma 
were cloned into pLKO.1 lentiviruses and were transfected into HEK392T cells with 
viral packaging constructs.  The resultant virions were used to infect wild type Jurkat T 
cells.  After antibiotic selection, the ability of C9orf9 knockdown (KD) Jurkats to signal 
to NF-κB was assessed using the same Igκ2-IFN-luc NF-κB reporter and β-galactosidase 
reporter that were used in the 293 activation assays.  Approximately 40 hours after 
transfection, cells were stimulated with αCD3 and αCD28 antibodies.  C9orf9 KD cells 
infected with shRNA #5 (sh5) activated the luciferase reporter 50% less that control cell 
infected with virions containing a non-target  (NT) shRNA.  This effect was specific to 
the TCR-to-NF-κB pathway.  TCR-to-NFAT and TNF-to-NF-κB signaling was not 
effected by C9orf9 knockdown (Figure 3). 
To confirm knockdown in Jurkat T cells, cell lysates were run on SDS-PAGE and 
transferred to PVDF membrane.  Membranes were blotted with an anti-C9orf9 antibody.  
Surprisingly, the lanes containing C9orf9 KD lysates were missing two bands when 
compared to lysates from the NT control cells (Figure 4).  One of these missing bands 
was 19kDa, the expected molecular weight of C9orf9.  The second band was 25kDa and 
initially inexplicable.  Further study suggested that the second band actually represented a 
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higher molecular weight splice variant of C9orf9.  This second variant was unlisted in 
RefSeq, so the initial interpretation of the second missing band was that it was due to 
post-translational modification of the 19kDa species of C9orf9.  However, in searching 
for a cDNA of C9orf9 that contained UTRs, I found a construct claiming to express a 222 
amino acid version of C9orf9 (approximately 25kDa and the size of the inexplicable 
band).  Interestingly, the reference link for this new cDNA connected to a RefSeq entry 
that had been replaced with the 168aa version of C9orf9.  Comparison of the two 
constructs and an analysis of the genomic locus indicated that Jurkat T cells did express 
both of these variants of C9orf9.  These two variants have their 165 N-terminal amino 
acids in common, but differ in their C-termini.  Failure of the mRNA to splice its fourth 
exon leads to the 222aa variant.  The 168aa variant is the result of mRNA splicing that 
removes a significant portion of the transcript and induces a frame shift.  That is to say, 
the entire coding region of the 168aa variant is contained in the transcript of the 222aa 
variant (Figure 5A).  The fifth exon of the 168aa variant is actually entirely present in the 
3’UTR of the 222aa variant.  Because shRNA targets transcripts at the mRNA level and 
leaves the endogenous DNA intact, it was impossible to design an shRNA hairpin that 
targeted only the 168aa variant of C9orf9  (Figure 5B).  ShRNA that targeted only the 
long form of C9orf9 were not effective at limiting anti-CD3/anti-CD28-induced NF-κB 
signaling in Jurkats as shRNA that targeted both forms, suggesting that both forms are 
required for signaling (Figure 5C). 
This hypothesis was confirmed when I attempted to rescue the C9orf9 sh5 
knockdown cells luciferase activation phenotype using only one shRNA-resistant C9orf9 
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construct.  Attempts to use either the 168aa variant or the 222aa variant both failed to 
rescue this phenotype.  Many attempts to rescue the phenotype using both constructs 
were initially unsuccessful (Figure 6A).  Changing the ratio of long:short C9orf9 had no 
effect on the constructs’ ability to rescue the phenotype (Figure 6B).  Pre-infecting Jurkat 
cells with virions encoding the shRNA-resistant rescue constructs before knocking down 
C9orf9 with shRNA containing virions was also ineffective (Figure 6C).  What was 
ultimately successful was using a pseudo-polycistronic vector which contains viral 2A 
sequences and allowed us to express both C9orf9 constructs under the same, very strong 
promoter.  The pULTRA vector contains the very strong human poly-ubiquitin promoter 
upstream of GFP, two viral 2A sequences, and two multi-cloning sites.  Viral 2A 
sequences are named for their host viruses, ie P2A for Porcine teschnovirus 1 and T2A 
for Thosea asigna virus.  They are short, 18-22aa sequences that utilize a sequence of 
conserved prolines to induce ribosomal skipping.  In essence, the presence of these 
prolines bends the nascent amino acid chain such that the ribosome is unable to complete 
the amino acid peptide linkage and ultimately generates separate peptide oligomers 
during the same readthrough.  By using both 2A sequences in the pULTRA vector, I was 
able to express GFP, long C9orf9, and short C9orf9 in the same plasmid and under the 
same promoter.  Interestingly, the orientation of the two C9orf9 variants in the vector was 
relevant because in the N-GFP-short C9orf9 –long C9orf9-C construct, the ribosomal 
skipping did not always occur, leading to the presence of one combined peptide of short + 
long C9orf9 (Figure 7A).  This construct failed to rescue the C9orf9 knockdown 
luciferase assays.  Contrastingly, the GFP-Long C9orf9 – short C9orf9 construct 
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generated the expected expression of distinct GFP, long C9orf9, and short C9orf9.  This 
construct was able to rescue the activation phenotype in C9orf9 KD Jurkats (Figure 7B). 
  Once it was identified that two C9orf9 constructs exist, both were tested for their 
ability to affect signaling in HEK293T cells.  Constructs expressing either the long or 
short form of C9orf9 enhanced CARD11-mediated activation of Ig2-IFN-Luc, the NF-
κB responsive luciferase reporter, in HEK293T cells. All forms of CARD11, both WT 
and hyperactive, were subject to this enhancement.  The mechanism of CARD11 
hyperactivity had no bearing on this enhancement and CARD11 mutants that decrease 
CARD11 inhibitory domain (ID) mediated auto inhibition, such as ΔID, C49Y, L251P, 
F123I, and L225LI,  as well as CARD11 mutants that have enhanced Bcl10 recruitment, 
such as C49S, Y98F, and T117A [10] were affected by C9orf9 expression (Figure 8A-E).   
In an attempt to determine which regions of C9orf9 affect signaling, and to 
understand the biological relevance of having two splice variants expressed, truncation 
constructs of C9orf9 were made and named for their terminating residues.  The H165 
construct expresses only the 165aa which are common to both the full length long and 
short isoforms of C9orf9.  Two other constructs are truncations of the long isoform and 
terminate at the Q189 and K206 residues, respectively (Figure 9).  When these constructs 
were tested in the 293 NF-κB luciferase reporter activation assay, K206 truncation 
enhanced wild type CARD11 signaling more than any of the other truncations, but less 
than full length long C9orf9.  The Q189 and H165 truncations did not enhance wild type 
CARD11 signaling in this assay, but neither did short C9orf9, which typically enhances 
wild type CARD11 signaling between 1.5 and 3-fold  (Figure 10A). 
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In the version of this assay using hyperactive L251P CARD11, similar results 
were seen.  The K206 truncation enhanced CARD11 L251P signaling to similar levels as 
the full length long form of C9orf9, even at a lower protein expression level.  In the same 
assay, the Q189 truncation enhanced L251P CARD11 signaling two fold, while the H165 
truncation enhanced L251P signaling almost 3 fold, the same as full length short C9orf9 
(Figure 10B). 
C9orf9 interacts with CARD11 cofactors 
 To determine which, if any, CARD11 cofactors interact with C9orf9, I performed 
immunoprecipitations of these proteins in 293T cells.  Cells were transfected with FLAG-
tagged cofactors and untagged C9orf9.  Anti-FLAG antibodies were used to pull down 
protein complexes onto Protein G sepharose beads, and the complexes were then eluted 
with FLAG peptide.   
The first cofactor I examined was Bcl10, which is the most relevant to signaling 
as well as the most well characterized co-factor.  Interestingly, the full length long and 
short forms of C9orf9 interacted with Bcl10, as did the K206 truncation construct and the 
H165 construct.  The Q189 construct did not interact with Bcl10.  It may be that there is 
an element between residues H165 and Q189 which inhibits the interaction between 
C9orf9 and Bcl10, but which is “buried” in the full length version of the protein (Figure 
11A).  I next examined C9orf9 interaction with NEMO (IKKγ) and found the same 
results.  Only the version of C9orf9 which terminates at reside Q189 failed to 
demonstrate and interaction with NEMO-FLAG (Figure 11B). Similar results were also 
obtained when I investigated C9orf9 interaction with TAK1 (Figure 11C). 
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C9orf9 knockdown decreases phosphorylation of pathway proteins 
Many proteins in the TCR-to-NF-κB pathway are activated by phosphorylation 
(Figure 12) [30], and many of these phosphorylation events are detectable via Western 
blot by phospho-specific antibodies.  If C9orf9 is influential in this pathway, I would 
expect that phosphorylation of pathway proteins will be decreased in C9orf9 knockdown 
Jurkat cells when compared to control cells.  In these experiments, cells were stimulated 
with anti-CD3 and anti-CD28 antibodies at 37°C for the indicated lengths of time.  Cells 
were harvested and lysed in IP lysis buffer plus protease inhibitor cocktail then run on 
SDS-PAGE and analyzed by Western blot (Figure 13).  Analysis of PKCθ 
phosphorylation at residue T538 also showed decreased phosphorylation in the C9orf9 
knockdown cells as compared to control cells.  IκBα phosphorylation was also decreased, 
but to a lesser degree than PKCθ phosphorylation.  In normal signaling, the 
phosphorylation and subsequent degradation of IκBα is what allows NF-κB to translocate 
to the nucleus and begin signaling.  I therefore analyzed degradation of total IκBα.  I did 
not see the clear lack of IκBα degradation we would expect with the decreased levels of 
NF-κB signaling we measure by luciferase assay and the clear differences in 
phosphorylation we observe higher in the TCR-to-NF-κB pathway.   
C9orf9 knockdown does not lead to cell death in OCI-LY3 DLBCL cells 
OCI-Ly3 cells are a cell line derived from Activated B Cell Diffuse Large B Cell 
Lymphoma (ABC DLBCL) patient samples.  They contain an endogenous allele of the 
L251P mutation of CARD11 and require CARD11 for survival [25].  I hypothesized that 
because C9orf9 appears to be an enhancer of CARD11 signaling in 293T cells and Jurkat 
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T cells it would also play a role in CARD11-mediated survival of OCI-Ly3 DLBCL cells.  
Virions containing the pSRGN vector with C9orf9 shRNA and packaged with pCL-Eco 
were made in 293T cells and used to infect OCI-Ly3 cells expressing the ecotropic 
receptor mCAT1.  A non-target shRNA was used as a negative control and an shRNA 
targeting CARD11 was used as a positive control.  In this system, cells infected with the 
pSRGN vector will express GFP and be detectable in the FITC channel of a flow 
cytometer.  By tracking the percent of live cells which are GFP positive, conclusions can 
be drawn about the effects of the shRNA expressed by the pSRGN vector on cell 
survival.  OCI-Ly3 cells infected with a CARD11-targeting shRNA will die within 7-14 
days, while 90% of cells infected with the non-target hairpin will survive.  Surprisingly, I 
was unable to demonstrate a significant difference in cell survival between cells infected 
with the non-target hairpin and cells infected with the C9orf9 targeting hairpin (Figure 
14).  Several possibilities exist to explain this result.  First, the shRNA may not 
successfully target C9orf9 in OCI-LY3 cells. Although Western blotting of sorted GFP 
positive cells could show that the C9orf9 hairpin is effective at knocking down protein in 
surviving cells, in the case of a partially effective hairpin, a result of C9orf9 expression in 
the sorted cells would not confirm the lack of a requirement of C9orf9 for cell survival, 
as the cells in which C9orf9 was knocked down could be dead and therefore not able to 
be isolated by cell sorting.  Because of the potentially inconclusive nature of the assay, 
cell sorting and subsequent Western blotting for C9orf9 in C9orf9 KD OCI-Ly3 cells was 
not performed.  Secondly, the role of C9orf9 on OCI-Ly3 cell survival may be more of a 
modulating role than a requirement for survival; in this case, the effect of C9orf9 
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knockdown on survival might be subtle enough as to not appear significant in this assay.  
Third, C9orf9 may play no role in CARD11-mediated cell survival of OCI-LY3 cells.  
Given the current data, it is impossible to distinguish which of these possibilities is true in 
the described assay.   
C9orf9 knockout mouse CRISPR design and characterization 
The CRISPR/Cas9 system has drastically shortened the length of time required to 
make knockin and knockout mice.  In connection with the JHMI Transgenic Mouse Core, 
I made use of this new technology to design and create a C9orf9 global deletion mouse.  I 
targeted the second exon of mouse C9orf9, on Chromosome 2, which contains the start 
methionine and initial coding region of C9orf9 (Figure 15).  It is important to target an 
upstream region of a gene when using CRISPR because if a more downstream region is 
left intact, the resultant message may be too long to be degraded by nonsense-mediated 
decay.  Using the Zhang lab’s website (crispr.mit.edu), I identified several potential 
PAMs (protospacer adjacent motifs) with low probabilities of off-target effects.  I chose 
one that would target a region approximately 10 amino acids downstream of the start 
codon, which I hoped would maximize the probability of nonsense mediated decay of any 
resultant transcript.  Instead of relying solely on non-homologous end joining (NHEJ) to 
repair the double stranded break induced by Cas9 and introduce helpfully disrupting 
mutations, I opted to use a long oligo to achieve homologous recombination.  Using this 
oligo, I inserted an AvrII site (CCTAGG) into the protospacer of the repaired DNA.  This 
achieved several goals:  First, I inserted an inframe stop codon ten amino acids 
downstream of the start codon.  Second, by adding a restriction site, I was easily able to 
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confirm the presence of the stop codon during genotyping.  Finally, by inserting the 
restriction site in the middle of the protospacer, I ensured that any residual Cas9 protein 
in the embryonic cells can’t target the repaired DNA.   
To create the necessary constructs for embryonic injection, I followed the 
Jaenisch group methodology [31].  Using their PX330 construct which contains the 
sequences for both Cas9 and the sgRNA/tracr chimera, I inserted my specific protospacer 
and generated RNA for both constructs.  I used a 126bp DNA oligo to induce homology-
directed repair (HDR).  The injection mixture contained 25ng/µL (2µg total) Cas9 
mRNA, 1µg sgRNA, and 2µg DNA oligo in 80ul H2O and was injected into single cell 
C57/Black 6 embryos by the JHMI Transgenic Mouse Core.   
To genotype the resultant embryos, I isolated DNA from ear punches using 
ethanol precipitation and amplified a 640bp region of chromosome 2.  Overnight 
digestion of the entire PCR product with AvrII generated a 414 bp fragement and a 228 
bp fragment in alleles with the AvrII site from HDR.  I was easily able to distinguish 
homozygous knockout mice by their lack of the initial 640bp amplified product as both 
copies were digested.  Heterozygous individuals displayed all three potential DNA 
fragments, and DNA from homozygous wild type individuals remained uncut with only 
the resultant 640bp fragment (Figure 16). 
Although several of the initial pups had the desired recombination as indicated by 
the presence of the AvrII site, only one of these individuals achieved germline 
transmission and passed the disrupted C9orf9 allele to its offspring.  The existence of 
mice which displayed evidence of recombination in DNA taken from ear punches, but 
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which failed to achieve germline transmission of the mutation, can be attributed to 
mosaicism caused by delayed or incomplete action of the Cas9 during early embryonic 
development.  It is impossible to predict whether Cas9 will be effective in the single cell 
embryo or in one or more of the daughter cells at the next stages of embryonic 
development, so it is important to always consider the possibility of mosaicism in the 
initial mouse pups.  Having more pups born will increase the odds of getting germline 
transmission of your targeted gene.  It is also important to test for expression of your 
targeted protein in multiple tissues if possible (in the case of a global deletion such as 
this).  This will confirm that the target mutations are present in the DNA in multiple cell 
types and that the resultant mRNA transcript is being degraded consistently across cell 
types.  In this case, Western blotting of mouse testes, where C9orf9 is most highly 
expressed, demonstrated a clear lack of protein expression of the short isoform of C9orf9 
in the C9orf9 KO mice (Figure 17).   
To assess the role of C9orf9 knockdown in the murine immune system, immune 
system development and B and T cell activation were analyzed via flow cytometry. All 
experiments were performed in 7-12 week old mice.  When compared to wild type mice, 
splenic T cell numbers in C9orf9 KO mice were grossly normal.  There were no 
significant differences in total CD3 positive cells, CD4 single positive cells, or CD8 CD 
positive cells.  Numbers of CD4+CD25 double positive Treg cells were also normal (data 
not shown).  CD4+CD25- cells were stratified on CD44 and CD62L to identify naïve, 
memory, and effector subsets as described [32].  There were no significant differences 
among these subsets, indicating that splenic T cell development in C9orf9 KO mice is 
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grossly normal (Figure 18B).  Thymic T cell development in C9orf9 KO mice was also 
determined to be normal.  Cells isolated from the thymus of 8-10 week old mice were 
stained for CD3, CD4, and CD8.  Because T cells undergo development and 
differentiation from CD4-CD8- through CD4+CD8+ to CD4 and CD8 single positive 
stages in the thymus, I looked at the relative numbers of each of these subsets and found 
them to be normal.  CD4-CD8- cells go through four developmental stages, termed DN1-
4, in the thymus.  These stages can be identified by the surface expression of CD25 and 
CD44, starting with CD44+CD25- (DN1), moving through CD44+CD25+ (DN2), to 
CD44-CD25+ (DN3), and ending with CD44-CD25- (DN4).  All for DN stages were 
normal in C9orf9 KO mice when compared to gender and age matched WT controls 
(Figure 18A).   
Splenic and bone marrow B cell development were also assayed by flow 
cytometry. B cell development is divided into several stages depending on the status of 
V(D)J recombination of the heavy and light chains of the Ig locus.  The variable region of 
the heavy chain locus is made up of many V, D, and J segments that can be recombined 
in different ways to create antibody diversity.  These joins are also accompanied with 
nucleotide insertions to increase the level of diversity of the recombined fragments. 
V(D)J recombination starts at the heavy chain locus with an initial D-J join which is 
followed by a V-DJ join. The resultant heavy chain is transported to the cell surface to be 
tested for functionality alongside the surrogate light chain.  Once a function heavy chain 
has been made, recombination of the light chain begins.  These various stages of B cell 
development have been named and are also accompanied by up and downregulation of 
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additional cell surface markers.  Pre-pro Bs, Pro Bs, Pre Bs, and Immature Bs, can be 
identified by their expression of B220, CD19, CD43 and IgM according to the following 
chart in Figure 19A [33]. 
 Bone marrow tissue was isolated from C9orf9 KO and age and gender-matched 
WT mice   Single cell suspensions were made and stained for the appropriate B cell 
markers.  Cells were initially stratified on B220 and CD19.  B220+CD19- cells were then 
stratified on CD43 and IgM.  B220+CD19-CD43+IgM- cells were classified as pre-pro B 
cells.  B220+CD19+ cells were also then stratified on CD43 and IgM. 
B220+CD19+CD43+IgM- cells were classified as proB cells.  B220+CD19+CD43-IgM- 
cells were classified as preBs, and B220+CD19+CD43-IgM positive cells were classified 
as immature B cells.  All of the described subsets were indistinguishable between 
C9orf9KO mice and WT mice, indicating no significant differences in bone marrow B 
cell development between genotypes (Figure 19B).  Splenic B cells were also analyzed 
for makers of development and differentiation.  In one scheme cells were stained with 
antibodies against CD23, CD21, and IgM.  Four different developmental stages were 
examined based on these markers.  Marginal zone B cells were defined as being CD23-
CD21+IgM+.  Transitional 1 cells were defined as CD23-CD21-IgM+.  Transitional 2 
cells were defined as CD23-CD21+IgM+.  Finally, mature follicular zone B cells were 
defined as being CD23-CD21-IgMlow [34].  There were no differences in these stages of 
differentiation between C9orf9 KO mice and WT mice (Figure 20A and B). 
Splenic B and T cells were also analyzed for their ability to upregulate activation 
markers and to proliferate in response to stimuli [35,36]. Splenic B cells were isolated 
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using the MACS Pan B cell Kit II (Miltenyi).  Cells were stained with 2µM CFSE 
Invitrogen CellTrace CFSE.  10µg/mL anti IgM, or 20 µg/mL LPS were used to stimulate 
the B cells.  Proliferation was measured by change in MFI after 72 hours incubation at 
37°C in 5% CO2 and 95% humidity.  C9orf9 KO B cells proliferated similarly to WT B 
cells upon stimulation (Figure 21A).  Activation was also measured by the upregulation 
of cell surface markers after 24 hours of the described stimuli.  There was no difference 
in the upregulation of  CD86, MHC Class II, or CD25 in C9orf9 KO B cells as compared 
to WT B cells (Figure 21B) [35, 36]. 
T cells were analyzed in a similar fashion to B cells to determine their responses 
to stimuli. CD4 and CD8 T cells were isolated using the MACS CD4 and CD8 negative 
selection kits (Miltenyi).  Cells were stained with 1µM CFSE.  Cells were stimulated 
using 3µg/mL plate bound anti-CD3 in the presence or absence of 2µg/mL soluble anti-
CD28.  Proliferation was measured by change in MFI after 72 hours incubation at 37°C 
in 5% COC in 5% CO2 and 95% humidity. C9orf9 KO T cells proliferated similarly to 
WT T cells upon stimulation (Figure 22A).  Activation was also measured by the 
upregulation of cell surface markers after 24 hours of the described stimuli.  There was 
no difference in the upregulation of CD25, CD44, or CD69 in C9orf9 KO CD4T cells as 
compared to WT CD4T cells (Figure 22B) [37].   
I also tracked gentoypes of the offspring born from het-het crosses.  Of 137 pups 
born, 39 pups (28%) were WT, 72 (52%) were heterozygous, and 26 (19%) were C9orf9 
KO.  This is slightly out of the expected Mendelian ratio of 25%-50%-25%.  
Interestingly, this pattern mimics that seen in an early description of Bcl10 KO mice [37].  
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In their system, about 1/3 fewer Bcl10 KO mice were born than were expected.  Day 
E10.5 fetal mice were extracted and were found to have significant neural tube defects 
which lead to embryonic lethality.  It is possible, given the interaction between Bcl10 and 
C9orf9 in vitro that a defect in C9orf9 may lead to the same type of embryonic defect 





















































Figure 1: Structure of CARD11 and relevant gain of function mutations. Schematic 
diagram of the domains of CARD11, including the CARD, LATCH, Coiled Coil, 
Inhibitory, PDZ, SH3, and GUK domains.  Relevant gain-of-function mutations in the 
CARD, LATCH, and Coiled Coil domains are indicated. 
Figure 2: Activation of NF-κB in 293Ts by short C9orf9 and CARD11.  HEK293T 
cells were transfected with 20ng Igκ2-IFN-luc, 6ng pCSK-LacZ and the indicated 
amounts of DEST-V5-short C9orf9 and/or the indicated amounts of pc-Myc-CARD11.   
Figure 3: C9orf9 has a specific effect on TCR-to-NF-κB signaling in Jurkat T cells.  
A. Jurkat T cells were transfected with 1500ng Igκ2-IFN-luc, 200ng pCSK-LacZ, and 
1300ng pcDNA3 and stimulated for 5 hours with anti-CD3/anti-CD28.  Jurkat T cells 
were transfected with 1500ng NFAT-luc, 200ng pCSK-LacZ, and 1300ng pcDNA3 and 
stimulated for 5 hours with anti-CD3/anti-CD28. C. Jurkat T cells were transfected with 
1500ng Igκ2-IFN-luc, 200ng pCSK-LacZ, and 1300ng pcDNA3 and stimulated for 5 
hours with anti-CD3/anti-CD28 or TNF. 
Figure 4: Western blot of C9orf9 knockdown Jurkat lysates indicates two isoforms 
of C9orf9.  Western blot analysis of lysates from C9orf9 knockdown or control Jurkat T 
cells.  A blot for IKKα is shown as a loading control. 
Figure 5: Structure of C9orf9 locus and locations of shRNA targeting. A. A 
schematic diagram of the chromosomal locus of C9orf9 indicating the locations of the 
UTRs and coding regions and showing the relative positioning of  these with regards to 
the short and long isoforms.   B.  A diagram of the long mRNA transcript of C9orf9.  The 
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coding region is translated and the targets of three shRNA hairpins are highlighted. C.  
Jurkat T cells were were transfected with 1500ng Igκ2-IFN-luc, 200ng pCSK-LacZ, and 
1300ng pcDNA3 and stimulated for 5 hours with anti-CD3/anti-CD28. 
Figure 6: Single isoform rescue of C9orf9 knockdown Jurkats is unsuccessful.  
Jurkat T cells were transfected with 1500ng Igκ2-IFN-luc, 200ng pCSK-LacZ, and 
stimulated for 5 hours with anti-CD3/anti-CD28. In all panels, NT indicates cells infected 
with a non-target shRNA, while C9orf9 sh5 indicates that cells were infected with an 
shRNA targeting C9orf9.  A.  Cells were also transfected with the indicated nanogram 
amounts of pEBB short sh5-resistant C9orf9.   B. Cells were also transfected with the 
indicated nanogram amounts of pEBB long sh5-resistant C9orf9. C.  Cells were 
transfected with the indicated nanogram amounts of pcDNA3 sh5-resistant short C9orf9 
and pCMV-XL5 sh5-resistant long C9orf9.  D. Cells were pre-infected with empty 
pCLIN3A or pCLIN3A sh5-resistant short C9orf9 before infection with the relevant 
shRNA. 
Figure 7: Pseudo-polycistronic vector expresses two isoforms of C9orf9 and 
successfully rescues C9orf9 knockdown phenotype in Jurkat T cells.  A. Western blot 
analysis of HEK293T cells transfected with pcDEST-V5 short C9orf9, pCMV XL5 long 
C9orf9, pULTRA short C9orf9, pULTRA short + long C9orf9, pULTRA long C9orf9, 
pULTRA long + short C9orf9, or pc-eGFP in the presence or absence of pc-myc L251P 
CARD11.  B. Jurkat T cells were transfected with with 1500ng Igκ2-IFN-luc, 200ng 
pCSK-LacZ, 1000ng pcDNA3, and 300ng total of pULTRA long + short sh5-resistant 
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C9orf9 and empty pULTRA as indicated and stimulated for 5 hours with anti-CD3/anti-
CD28 
Figure 8: C9orf9 enhances the ability of hyperactive CARD11 and Bcl10 to signal to 
NF-κB.  HEK293T cells were transfected with 20ng Igκ2-IFN-luc, 6ng pCSK-LacZ and 
the indicated amounts of pc long C9orf9-GFP or 12.5ng of pc-EGFP in the presence or 
absence of the indicated nanogram amounts of  pc-Myc-CARD11 L251P and A. L225LI 
CARD11 B. F123I CARD11 or C. C49Y CARD11.  D. Y98F CARD11 E. T117A 
CARD11 F. HEK29T cells were transfected with 20ng Igκ2-IFN-luc, 6ng pCSK-LacZ 
and 200ng DEST-FLAG short C9orf9, pCMV XL5 long C9orf9, 30ng pc FLAG-Bcl10, 
or a combination of C9orf9 and Bcl10.  Panels A, B, and C include Western blot analysis 
of lysates from these transfections. 
Figure 9: Structure of C9orf9 truncation constructs. Schematic of C9orf9 truncation 
constructs.  For each construct, the starting methionine is labeled M1 while the 
terminating residue is indicated on the right of the diagram.  For each construct H165 is 
marked as the splice site where the short and long isoforms diverge.  T168 is labeled with 
(*) in short C9orf9 to indicate that the three resides after H165 are different in this 
construct than in the Long, K206, and Q189 constructs. 
Figure 10: C9orf9 truncation constructs have different effects on CARD11 
signaling. . HEK293T cells were transfected with 20ng Igκ2-IFN-luc, 6ng pCSK-LacZ 
and the indicated amounts of the appropriate pcC9orf9-GFP constructs in the presence or 
absence of  A. 30ng pc-Myc-CARD11 or B. 30ng L251P CARD11.  Western blot 
analysis of lysates from these transfections is included in both panels. 
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Figure 11: C9orf9 truncation constructs interact with CARD11 cofactors. HEK293T 
cells were transfected with the indicated nanogram amounts of the appropriate pcC9orf9 
construct and 200 ng of A. pcFLAG-Bcl10 B. pcFLAG-NEMO C. CMV FLAG mTAK1.  
Anti-FLAG IPs were performed and the results were analysed by anti-C9orf9 and anti-
FLAG Western blots. 
Figure 12: Schematic diagram of CARD11’s role in antigen receptor signaling. 
Schematic diagram of the TCR-to-NF-κB and BCR-to-NF-κB pathways indication their 
convergence on CARD11. 
Figure 13: Activation of TCR pathway proteins is affected by C9orf9 knockdown in 
Jurkat T cells.  Jurkat T cells were stimulated with anti CD3/antiCD28.  Cells were 
lysed in the presence of protease inhibitor cocktail (Sigma P8340 at 1:1000), 10mM 
sodium fluoride, 2.5mM sodium orthovanadate, and 10mM β-glycerophosphate.  Equal 
volume of lysate was run per lane on 12% SDS-PAGE and results were analyzed via 
Western blot. 
Figure 14: C9orf9 knockdown does not affect OCI-Ly3 cell line survival.  Retroviral 
constructs based on the pSUPER-retro-Neo+GFP vector containing either a non-target 
shRNA, a CARD11-targeting shRNA, or a C9orf9-targeting shRNA were packaged using 
pCL-Eco and used to infect the OCI-Ly3 DLBCL cell line.  Three days after infection 
cells were analyzed by FACS and the percent GFP+ (indicating live cells infected with 
the shRNA vector) were calculated.  This procedure was repeated at 6, 10, 13, and 16 
days post infection. 
53 
 
Figure 15: C9orf9 locus and CRISPR targeting design. A.  The schematic of the 
C9orf9 locus which indicates the CRISPR sgRNA target site.  B.  The sequence of the 
second exon of C9orf9 and some of the surrounding introns.  Regions of interested are 
indicated by highlighting:  blue indicates conserved intron regions, pink indicates the 
extent of the 126bp oligo used for homology directed repair, yellow indicates the PAM, 
green indicates the protospacer sgRNA target, and purple indicates the locations of the 
sequencing primers used in genotyping pups.   
Figure 16: PCR genotyping strategy of C9orf9 knockout mice. A. A schematic 
cartoon indicating the potential outcomes of WT, C9orf9 KO, and heterozygous pups in 
the described genotyping strategy.  B. An image taken from the genotyping PCR of a 
control C57/B6 WT mouse and the first seven pups born after CRISPR genome editing of 
single-cell embryos.  Each mouse has two lanes, a control lane and one where the sample 
was digested overnight with 0.5ul AvrII.  Although 12002, 12006, 12007, and 12008 all 
appear to have at least one copy of the desired gene modification, it is important to note 
that only 12008 transmitted this allele to its offspring. 
Figure 17: C9orf9 expression is decreased in C9orf9 knockout mice.  Mouse testes 
from WT C57/B6 and C9orf9 KO mice were harvested, lysed, and protein was 
quantitated by Bradford assay.  20ug total protein was run per lane on 12% SDS-PAGE.  
Protein was transferred to PVDF and membranes probed for C9orf9 and GAPDH as a 
loading control.   
Figure 18: T cell development in the thymus and spleen is normal in C9or9f 
knockout mice A. Mouse thymocytes were stained for T cell development and analyzed 
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by flow cytometry.  Cells were gated on CD3+ and then stratified on CD4+ and CD8+.  
CD4+ cells were gated and stratified on CD25 to distinguish Treg cells from other 
effector cells.  CD4-CD8- cells were stratified on CD25 and CD44 to look at the Double 
Negative 1-4 (DN1-4) developmental populations. B. Mouse splenocytes were stained for 
T cell development and analyzed by flow cytometry.  Cells were gated on CD3+ and then 
stratified by CD4+ and CD8+.  CD4+ cells were stratified on CD25 to distinguish Treg 
cells from other effector cells.  CD4+CD25- cells were then stratified on CD44 and 
CD62L to compare naïve (CD44med CD62L+), memory (CD44hiCD62L+) and effector 
(CD44+CD62L-) populations. 
Figure 19: B cell development in the bone marrow of C9or9f knockout mice is 
normal.  A. Chart comparing the expression of B220, CD19, CD43, and IgM in Pre-
ProB cells, proB cells, preB cells, and immature B cells.  B.  Mouse bone marrow cells 
were stained for B cell development and analyzed by Flow Cytometry.  Cells were 
stratified on B220 and CD19.  B220+CD19- cells were stratified on CD43 and IgM to 
identify Pre-Pro B cells.  B220+CD19+ cells were stratified on CD43 and IgM to identify 
Pro B, Pre B, and Immature B cells.  Wild type mice are on the top row of the panel 
while C9orf9 KO mice are on the bottom row of the panel.   
Figure 20: Splenic B cells show normal development in C9orf9 knockout mice.  
Mouse splenocytes were stained for B cell development and analyzed by flow cytometry.  
Males are in the far left column, while two female mince per genotype were analyzed in 
the center and right hand columns.  Wild type mice are at the top of each panel and 
C9orf9 KO mice are on the bottom row of each panel.  Cells were stratified on CD23.  A. 
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CD23- cells were then stratified on CD21 and IgM to compare Marginal Zone B cells 
(MZB cells, IgMhiCD21hi) and Transitional 1 cells (IgMhiCD21lo).  B. CD23+ cells 
were stratified on IgM and CD21 to compare Transitional 2 cells (IgMhiCD21hi) and 
mature cells (IgM-CD21lo). 
Figure 21: B cell activation in C9orf9 knockout mice is normal.   Mouse B cells 
analyzed for activation after stimulation. In both panels, green demotes stimulated C9orf9 
KO cells, orange denotes unstimulated C9orf9 KO cells, blue indicates stimulated wild 
type cells and pink represents unstimulated wild type cells.  A. Cells were loaded with 
CFSE (final concentration 2µM) and stimulated with 10µg/mL anti-IgM or 20ug/mL 
LPS.  After 72 hours cells were harvested and analyzed for division by flow cytometry.  
B. Cells were stimulated overnight with anti-IgM or LPS.  Cells were then harvested and 
stained for the activation markers CD25, CD86, and MHC Class II and analyzed by flow 
cytometry.   
Figure 22: T cell activation in C9orf9 knockout mice is normal.   Mouse T cells were 
analyzed for activation after stimulation.  In both panels, green demotes stimulated 
C9orf9 KO cells, orange denotes unstimulated C9orf9 KO cells, blue indicates stimulated 
wild type cells and pink represents unstimulated wild type cells. All stimulations were 
performed with 3µg/mL plate bound αCD3 and 2 µg/mL soluble αCD28.  A.  CD4+ (left 
panel) and CD8+ (right panel) cells were loaded with CFSE (Final concentration 1µM) 
and incubated for 72 hours in the presence or absence of stimulation.  Cells were 
harvested and analyzed for division by flow cytometry.  B. CD4+ cells were incubated 
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overnight in the presence or absence of stimulation.  Cells were harvested and stained for 





Reporter assays of 293T cells:   
HEK293T cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 
10% heat inactivated fetal bovine serum, 2mM glutamine, and 100 U/ml each of 
streptomycin and penicillin. Cells were maintained at 37°C in humidified atmosphere 
with 5% CO2.  For transfection, 0.5mL cells were plated at 1.8x10
5
/mL in 24 well plates.  
24 hours after plating, cells were transfected using the calcium phosphate method.  
Briefly, 376ng total DNA were transfected, including 20ng of the IgK2-IFN-Luc reporter 
plasmid [38] or the NFAT-Luc reporter plasmid (Stratagene) [9], 6ng of the pCSK-LacZ 
plasmid [3], and up to 350ng of the expression constructed to be tested.  Each sample was 
transfected with pcDNA3 filler DNA to maintain the 376ng total.  Media was changed 
between 20-26 hours after transfection, and cells were harvested between 44-48 hours 
after transfection.  Harvest was performed by lysing cells in 100ul 1x reporter lysis buffer 
(Promega).  Cells were scraped and spun at 16,000 x g for 5 minutes to pellet cells.  20ul 
of lysate were used to measure luciferase activity using the Promega luciferase reporter 
system and read on a Berthold TriStar LB941 luminometer. β-Galactosidase (β-Gal) 
activity was measured using 10ul lysate, 15ul 1x Promega lysis buffer, and using a 
chemiluminescent reporter system (Roche) according to the manufacturer’s instructions.  
Relative signaling activity was determined by subtracting the background signal as 
measured in untransfected cells, dividing the luciferase activity by the β-Gal activity, and 
normalizing to a reference sample transfected with 350ng of empty expression vector.   
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Jurkat reporter assays: 
Jurkat T cells were grown in RPMI media supplemented with 10% heat-inactivated fetal 
bovine serum, 2mM glutamine, 100 U/mL each of streptomycin and penicillin, and 50µM 
β-mercaptoethanol.  Cells were maintained at 37°C in humidified atmosphere with 5% 
CO2.   On the day of transfection, 5x10
5
 cells were plated in 2mL of media in 6-well 
plates.  In all assays, cells were transfected with 1500ng of either IgK2-IFN-Luc or 
NFAT-LUC, 200ng of pCSK-LacZ, and 1300ng of expression and/or filler DNA, for a 
total of 3ug.  DNA was incubated with 9ul of LT-1 (Mirrus) transfection reagent in the 
presence of serum-free RPMI before being added dropwise to cells.  40-44 hours after 
transfection, cells were resuspended in 1mL of medium with or without 1µg/mL each of 
anti-human CD3 (BD clone UCHT1), anti-human CD28 (BD), and anti-mouse IgG1 
(BD).  Alternatively, cells were resuspended in 1mL media containing 10ng/mL TNF 
(Sigma).  Cells were incubated 4-6 hours, and were then harvested and lysed in 150µL 1x 
Promega lysis buffer.  Cells were spun as above to remove debris.  Luciferase activity 
was measured using 50µL lysate, while β-Gal activity was measured using 25µL lysate 
and the reporter system described above.   
HEK293T Immunoprecipitation 
Cells were transfected using the calcium phosphate method described above, except that 
cells were 5x10
5
 cells were plated in 2mL media in 6 well plates. A total of 2µg DNA 
was transfected 20-24 hours after plating.  Media was changed 20-24 hours after 
transfection, and cells were harvested 44-48 hours after transfection.  Cells were 
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harvested in ice and lysed in 500µL IP Lysis buffer containing 150mM NaCl, 1mM 
EDTA, 10% glycerol, 1% IGEPAL, 50mM HEPES  pH 7.9, and a protease inhibitor 
cocktail (Sigma P8340).  Cells were spun for 10min at 16,000 x g at 4°C to remove 
debris.  450µl lysate were transferred to a new tube for preclearing.  Lysates were 
precleared once for 30 minutes with rotation at 4°C using a 7ul bed volume of Protein G 
Sepharose 4 Fast Flow (GE).   10µL of precleared lysate was saved for Western Blotting.  
Immunoprecipitation was achieved by incubating 40µl precleared lysate with 1µg rabbit 
anti-Flag antibody (Sigma F7425) overnight at 4°C with rotation.  A 7µl bed volume of 
protein G Sepharose that had been blocked overnight in 1% insulin was added to each 
sample and rotation continued at 4°C for one hour.  After this incubation, the beads were 
washed four times with 1mL IP Lysis Buffer for 5 minutes with rotation at 4°C.  After 
the final wash, the resulting complex was eluted from the bead/antibody complex using 
30µl 0.1mg/mL FLAG peptide  (Sigma).  Two thirty-minute elutions were performed and 
the elutions were pooled together and spun briefly.  30µL of the resulting eluate was 
boiled with presence of 15µL 3X sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) loading buffer (150mM Tris-HcL pH6.8, 6% SDS, 0.3% 
Bromophenol blue, 30% glycerol, 15% β-mercaptoethanol) and resolved on 12% SDS-
PAGE gels.  Samples were transferred to polyvinylidene difluoride (PVDF) membranes 
and blotted for C9orf9 (Sigma HPA022243 or Abcam 171036) and FLAG (Sigma 





Stable knockdown and Rescue of C9orf9 
A hairpin targeting C9orf9 (C9sh5, target sequence 5’-
AGAGCTACATGGAACACTACT-3’) or a non-targeting hairpin (ShNT, target 
sequence 5’--CAACAAGATGAAGAGCACCAA-3’) were cloned into the pLKO.1 
vector.  Viral packaging was performed by plating 9x10
4
 HEK293T cells in 0.5mL media 
in 24 well plates.  24 hours later the calcium phosphate method was used to transfect 
100ng pMDL-RRE, 35ng RSV-Rev, and 50ng CMV-Vsvg.  Media was removed 24 
hours after transfection and 300µL fresh media was added to concentrate the virus.  
Supernatants containing viral particles were collected 20-24 hours after the media 
change.  Supernatants for each line were pooled and spun for 5minutes at 4000 rpm to 
remove any cellular debris.  100µl viral supernatant was added to 1.5x10
5
 wild type 
Jurkat T cells in 24-well plates to bring the final volume to 300µL. 24 hours after 
infection, infected cells for each line were pooled, spun for 5 minutes at 1400 x g, and 
resuspended in fresh RPMI containing 0.5µg/mL puromycin and selected for 5 to 8 days.  
Knockdown was assessed by Western blot analysis using an anti-C9orf9 antibody.  For 
rescue assays, cells were transfected with 1500ng IgK2-IFN-Luc, 200ng pCSK-LacZ, the 
inidicated amounts of pULTRA rescue construct, and pcDNA3 empty expression vector 
such that the total DNA transfected was 3µg.  The pULTRA expression vector (Addgene 
Plasmid #24129) contains a human Ub promoter upstream of GFP and a multicloning 
region that can be used to create a pseudo-polycistronic vector where inserted constructs 
are separated by viral 2A sequences which allow for ribosomal skipping and the 
simultaneous expression of multiple inserts.  Rescue assays were conducted with a  
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construct which contains GFP-P2A-long C9orf9-T2A-short C9orf9 in which both 
versions of C9orf9 are sh5-resistant.  Cells were transfected with LT1 as described above, 
and luciferase activity was assessed as in previous experiments.   




 Jurkat T cells were stimulated with 1µg/mL each anti-human CD3, anti-human 
CD28, and anti-mouse IgG1 in a final volume of 1mL in 48 well plates for the indicated 
times.  Cells were harvested and kept on ice for at least 5 minutes to quench the reaction.  
The samples were spun for 5 min at 5000rpm at 4°C to pellet cells.  Cells were then lysed 
in 50µL IP Lysis Buffer plus 2.5mM sodium orthovanadate, 10mM sodium fluoride, and 
10mM β-glycerophosphate.  Cells were incubated on ice for 10 minutes, then spun for 5 
minutes at MAX rpm 4°C to pellet debris.  20µL lysate was boiled in the presence of 
SDS-PAGE loading buffer and resolved on 12% SDS-PAGE before being transferred to 
PVDF membrane.  Membranes were analyzed by Western blot using mouse anti-
Phospho-IκBα (Cell Signaling Technology, Inc. 9246S), rabbit anti-IκBα (Sigma sc-371),  
rabbit anti-C9orf9 (Sigma HPA022243),  rabbit anti-GAPDH (Cell Signaling 5174P), 
goat anti-PKCθ (Santa Cruz sc-1875), rabbit anti-phospho PKCθ T538 (Cell Signaling 
9377), rabbit anti-LAT (Cell Signaling 9166), and rabbit anti Phospho-LAT (Cell 





OCI-Ly3 infection and survival assay 
Virions containing the pSUPER.retro.neo+GFP (pSRGN, Oligoengine) vector with 
C9orf9 shRNA and packaged  with  pCL-Eco were made in 293T cells as previously 
described [10] and used to infect OCI-Ly3 cells expressing the ecotropic receptor 
mCAT1.  A non-target shRNA was used as a negative control (sense sequence 5’-
CAACAAGATGAAGAGCACCAA-3’, loop sequence 5’-CTCGAG-3’) and an shRNA 
targeting CARD11 (Sense sequence, 5’-TGGTCAAGAAGCTGACGATTC-3’,  loop 
sequence 5’-TTCAAGAGA-3’) was used as a positive control. C9orf9 was targeting 
using the same shRNA as in Jurkat experiments, but designed for pSRGN (sense 
sequence 5’-AGAGCTACATGAACACTACT-3’,  loop 5’-TTCAAGAGA-3’).  
Retroviral packaging was performed in HEK 293T cells.  5x10
5
 cells were plated in 2mL 
complete DMEM.  24 hours after plating 800ng pCL-Eco and 3200ng pSRGN vector 
were transfected using 10µL Lipofectamine 2000 (ThermoFisher) and 250µL Opti-MEM 
media.  24 hours post transfection the DMEM was removed and replaced with 1.5mL 
OCI medium, which is Iscove’s modified Dulbecco medium (IMDM) supplemented with 
20% human serum (Atlanta Biologicals S40110), 50 U/mL each of penicillin and 
streptomycin and 55µM β-mercaptoethanol.  OCI-Ly3 cells were plated at 4x10
5
 
cells/mL in 500µL OCI media.  Viral supe was collected and debris spun out by 
centrifugation.  500µL viral supe was added to OCI-Ly3 cells as well as polybrene to ao 
final concentration of 3µg/mL.  18-24 hours after infection, cells were spun down and 
resuspended in 1.5mL OCI media.  1mL additional OCI media was added 24 hours later.  
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3 days after infection, the percent of GFP positive cells was determined by flow 
cytometry on a BD LSRII and measurements were taken every three days thereafter.   
CRISPR Mouse 
Generally, the methodology of the Jaenisch group was used to generate the Cas9 mRNA 
and specific sgRNA against C9orf9 [31].  Specifically, annealed oligos were inserted into 
the PX330 vector (forward 5’- CACCGACTTCTGCTCGATGCTGCGG-3’, reverse 5’- 
AAACCCGCAGCATCGAGCAGAAGTC-3’).  The target region was amplified by 
PCR.  RNA was generated using the HiScribe T7 Quick High Yield Synthesis Kit (NEB 
E2050) and purified using the MEGAclear Transcription Clean-up Kit 
(ThermoFisher/Ambion AM1908).  A T7 transcription start site was inserted into PX330 
upstream of Cas9 to aid in Cas9 synthesis.  The mMessage mMachine T7 kit 
(ThermoFisher/Ambion AM1344) to perform in vitro transcription to generate Cas9 
mRNA and LiCl precipitation was performed for purification. The 126bp oligo HDR 




TTAGGTCTCACAGGACAGAAA-3’).  The injection mixture contained 25ng/µL (2µg 
total) Cas9 mRNA, 1µg sgRNA, and 2µg DNA oligo in 80ul H2O and was injected into 
single cell C57/Black 6 embryos by the JHMI Transgenic Mouse Core.   
 Pups from the resultant embryos were genotyped by amplifying a 640bp region 
of Chromosome 2 (forward primer: 5’- GCAGTGGTGAACAACTCGAAGGAC -3’, 
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reverse primer: 5’- GTGGGGAAACTGAGGCGTAGTG -3’) using the Roche FastStart 
Taq kit #04738357001 and digesting overnight with AvrII (NEB).   
Western blotting of mouse testes: 
Mouse testes from WT C57/B6 and C9orf9 KO mice were harvested, lysed in IP Lysis 
Buffer plus protease inhibitor cocktail as described above, and protein was quantitated by 
Bradford reagent (BioRad).  20ug total protein per lane was boiled in the presence of 3X 
SDS Sample Buffer and run on 12% SDS-PAGE.  Protein was transferred to PVDF and 
membranes probed for C9orf9 (Sigma HPA022243) and GAPDH (Cell Signaling 5174P).   
Flow Cytometry of Mouse B and T cells 
Mouse splenocytes, thymocytes, and bone marrow tissue was separated into single cell 
suspensions.  Red blood cells were lysed in ACK buffer (Quality Biologicals).  
Lymphocytes were resuspended in complete RPMI as described in the Jurkat cell 
protocol.  Miltenyi MACS negative selection kits were used to isolate CD4+ T cells, 
CD8+ T cells, or Pan B cells following the manufacturer’s instructions.  For 
developmental studies, antibodies against CD3 (BD 553061), CD4 (BD 553730), CD8 
(BD 563786), CD25 (BD 557192), CD44 (BD 560569), CD62L (BD 562910), 
B220/CD45R (BD 561880), CD19 (BD 557655), IgM (BD 553408), CD43 (BD 553271), 
CD23 (BE 553139), and CD21 (BD562797) were used.  In CFSE experiments, cells were 
loaded with Invitrogen CellTrace CFSE.  B cells were stimulated with 10µg/mL anti-IgM 
(ebioscience 16-5092-85) or 20 µg/mL LPS (Sigma L3012).  T cells were stimulated 
using 3µg/mL plate bound anti-CD3 (BD clone 3751) and 2µg/mL soluble anti-CD28 
(BD clone 145-2c11). Unstimulated samples were incubated in media only.  Proliferation 
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was measured after 72 hours incubation at 37°C in 5% CO2 and 95% humidity.  
Upregulation of surface activation markers was measured after 24 hours of stimulation 
using antibodies against CD25 (BD557192), CD86 (Biolegend 105031), MHC Class II 
I
ab
 (Biolegend 116419), CD69 (BD 553236), and CD44 (BD 560569) [36, 37].  Stains 
involving B cell surface markers were performed in the presence of FcR blocking using 
TruStain FcX (Biolegend 101320).  Cytometry was performed on a BD LSRII and 

















The role of C9orf9 in antigen receptor signaling 
Regulated antigen receptor signaling is critical for controlling the adaptive 
immune response.  Antigen receptor pathways are highly complex networks that must 
receive, integrate, transmit, and then interpret signals in the correct pro- or anti-
inflammatory action.  While much is known about the initial and final steps of 
TCR/BCR-to-NF-κB signaling, much remains to be clarified about the intervening steps. 
In order to identify previously unknown members of the TCR- and BCR-to-NF-
κB pathways, a high throughput protein-protein interaction screen was conducted using 
isolated, recombinant CARD11 and protein expression chips.  C9orf9 was identified as a 
potential interactor of CARD11 and further investigated for its ability to enhance 
CARD11 signaling.  Although the interaction with CARD11 was never confirmed, 
C9orf9’s ability to interact with the CARD11 cofactor Bcl10 helped clarify its ability to 
enhance CARD11 signaling.   
Many questions still remain about the mechanism of C9orf9 activity.  Tests of 
C9orf9 truncation constructs in the 293T cell NF-κB luciferase reporter assay indicate 
that there may be a region between amino acids H165 and Q189 in the long form of 
C9orf9 that acts as an inhibitory region and prevents it from interacting with Bcl10 and 
other cofactors.  Alternatively, there may be an activating region between amino acids 
Q189 and K206 in the long isoform which is required for C9orf9 interaction with Bcl10 
and activation of the pathway.  Further truncation studies could help clarify which of 
these two hypotheses is correct.  Additionally, the rescue experiments in C9orf9 
knockdown Jurkat T cells should be conducted with constructs that express the truncated 
68 
 
versions of long C9orf9 and the full length short version of C9orf9.  This is the best way 
to determine which residues of the long form are required for activity in endogenous 
settings.   
One of the challenges of this work was attempting to place C9orf9 epistatically in 
the antigen receptor pathway.  The data was in some ways contradictory, showing a 
greater effect of C9or9f knockdown upstream of CARD11 and Bcl10, at PKCθ and LAT, 
than the effect seen down stream of CARD11 at IκBα.  A few hypotheses are plausible 
from the current data.  C9orf9’s two isoforms may act in different places in the pathway, 
which seems to be the most plausible explanation for why both isoforms are required for 
signaling.  Preliminary evidence does not indicate that the two isoforms interact with 
each other in a complex, or that they both interact with the same cofactors in the same 
time in the same way, although more detailed experiments would be required to confirm 
that they interact at the same “step” of the pathway, the CBM complex, but with different 
complex members simultaneously.  Rather, it seems more likely that one form interacts at 
the level of the CBM complex and the other isoform interacts upstream of CARD11, at or 
above LAT.   
Alternatively, the unexpected change in LAT and PKCθ phosphorylation could be 
due to a feedback loop, where the C9orf9 isoforms act at the level of CARD11 and 
Bcl10, but changing levels of NF-κB activation feedback on to the same cells and prevent 
them from responding as well to antigen receptor stimulation as cells which have more 
successfully initiated NF-κB dependent transcription programs.  The existence of a 
feedback loop seems plausible because of the non-linear relationship between CARD11 
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expression and cellular activity.  One challenge of the C9orf9 truncation experiments in 
293T cells was getting equivalent expression of both C9orf9 and CARD11 across 
experiments.  The C9orf9 truncation constructs express at different levels in 293Ts, 
which is reasonable and consistent for these types of experiments and constructs.  
Preliminary experiments were conducted to determine which nanogram amounts of 
C9orf9 constructs gave equivalent levels of protein expression.  However, once these 
nanogram amounts were cotransfected into 293Ts with 30ng of CARD11, their 
expression changed.  For some constructs, co-expression with CARD11 increased C9orf9 
expression.  Expression of the full length long form of C9orf9 also increased CARD11 
expression, which interestingly correlated with that sample having the highest activation 
of the luciferase reporter of all the conditions tested in that assay.  This discrepancy in 
protein expression levels makes it difficult to interpret the degree to which the long form 
of C9orf9 enhances CARD11 signaling relative to other C9orf9 constructs.  However, it 
does suggest that activation of CARD11 initiates a transcription program which in turn 
upregulates CARD11 itself, allowing for even greater activation of the luciferase 
reporter.  This feedback loop would explain the discrepancies seen in LAT and PKCθ 
phosphorylation in C9orf9 KD Jurkats when compared to control cells.   
A third explanation for this unexpected result involves our current understanding 
of PKCθ placement in the antigen receptor pathway.  It is possible that PKCθ acts at 
multiple steps in the pathway, and not only at its currently understood placement 
upstream of CARD11 at the immunological synapse.  Interestingly, C9orf9 KD Jurkat T 
cells stimulated with PMA/ionomycin do display defective signaling in the luciferase 
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reporter assay but did not display a defect in PKCθ phosphorylation.  One complication 
of this result is that the mechanism of action of PMA/ionomycin stimulation is not 
entirely clear.  It is thought that PMA may act on PKCθ, but it is also thought to act at 
other, unspecified places in the pathway.  Because the exact step(s) of action of PM are 
unknown, it is difficult to explain where PKCθ may be acting or why these inconsistent 
results are seen in C9orf9 KD Jurkats.   
Separating the functions of the two isoforms of C9orf9 
The major obstacle of this project was dealing with the presence of two different 
isoforms of C9orf9.  Because of the orientation of the exons and the location of the splice 
site that generates the short isoform, the entire mRNA transcript of the short isoform is 
contained within the transcript of the long isoform.  Because shRNA targets mRNA 
transcripts, it is impossible to use this technology to specifically knockdown the short 
isoform.  While it was possible to specifically target the long isoform using shRNA, I did 
not spend much time pursuing the specific function of the long isoform because the long 
C9orf9 KD Jurkats did not have as strong of a phenotype in the NF-κB luciferase reporter 
assay as the dual C9orf9 KD cells.  It would be worth pursuing the long isoform specific 
knockdown phenotype to try to understand the specific function of the long isoform. 
A similar problem was encountered when designing CRISPR/Cas9-mediated knockdown 
of C9orf9 in mice.  Because CRISPR targets DNA, any intact code will be transcribed 
and potentially translated into protein.  It is therefore important to target a region within a 
few codons of the translational start site.  The structure of the C9orf9 locus and the 165 
N-terminal amino acids which are shared between the two isoforms make it impossible to 
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use CRISPR to target one isoform specifically.  Again, it will be extremely difficult to 
characterize the mechanism of action of C9orf9 without being able to specifically 
knockdown one isoform and isolate its contribution to C9orf9 function.  As technology 
changes, scientists interested in pursuing studies of C9orf9 function should pay attention 
to new developments in gene expression modification and apply new technologies to the 
problem of C9orf9 isoform specific knockdown.   
Further studies in the C9orf9 KO mouse model 
Several potential phenotypes were examined in the C9orf9 KO mice.  Basic 
development of B and T cells were analyzed and found to be normal.  Upregulation of 
activation in markers in B and T cells in response to stimulation was also normal, as was 
the ability of those cells to proliferate under stimulation.  Because of the phenotype 
present in C9orf9 KD Jurkat T cells, I expected to find a defect in B or T cell 
development or basic activation.  None of the expected defects were present.  There are, 
however, many other potential phenotypes in the KO mice which were not examined.  
These more complex in vivo models include tests of the ability to respond to T-dependent 
vs T-independent antigens, tumor challenge models, vaccine titer tests, and NK cell 
killing ability.    Tests of any of these functions could reveal an important role for C9orf9 
in the adaptive and innate immune systems.  Finally, the imbalance in the Mendelian ratio 
of pups born to het-het crosses suggests a potential neural tube defect like that seen in the 
Bcl10 KO mice.  Timed matings and examination of fetal development would confirm 
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